

SCIENTIFIC PROGRAMME

Course Directors

Eric Deutsch
Udo Gaipl

Faculty

Fernando Herrera Michele Mondini
Jamie Honeychurch Rianne Vaes
Claire Vanpouille-Box Gosse Adema

DAY 1 – SUNDAY 3RD MARCH:

Topic I: Introduction to the immune system, immunogenicity and adjuvanticity

Topic II: The impact of ionizing radiation on the immune response

Chair: TBC

Time	Duration	Lecture	Speaker
08.30 – 08.45	15	Welcome & Introduction of teachers	All
08.45 – 09.30	45	Overview of innate and adaptive immune system	Jamie Honeychurch
09.30 – 10.15	45	The cancer immunity cycle and the 5Rs	Claire Vanpouille-Box
10.15 – 10.45		<i>Coffee break</i>	
10.45 – 11.30	45	State of the art clinical immunology, from checkpoints blockers to CAR T cells	Michele Mondini
11.30 – 12.15	45	Immunological cell death, from apoptosis to necroptosis, pyroptosis	Udo Gaipl
12.15 – 13.15		<i>Lunch break</i>	
13.15 – 14.00	45	In situ cancer vaccines: local tumour destruction and immune stimulation for systemic tumour control	Gosse Adema
14.00 – 14.45	45	The influence of dose, fractionation and volume on the immune response to radiotherapy; immune contexture	Fernanda Herrera
14.45 – 15.15		<i>Coffee break</i>	
15.15 – 16.00	45	Impact of different radiation qualities (X-rays, alpha irradiation, Carbon ions) on immune response	Udo Gaipl
16.00 – 16.45	45	Side effects of radiotherapy, also linked to immunity	Rianne Vaes

SCIENTIFIC PROGRAMME

DAY 2 – MONDAY 4TH MARCH:

Topic III: Macrophages and anti-tumour immunity

Topic IV: Tumour immune microenvironnement

Topic V: Hypoxia; cancer vaccine and oligometastatic disease

Topic VI: Biomarkers for Radio-Immunotherapies

Chair: TBC

Time	Duration	Lecture	Speaker
08.30 – 09.15	45	Macrophages reprogramming modulates the immune tumour microenvironment in mouse models of HPV-driven cervical cancer	Michele Mondini
09.15 – 10.00	45	DNA damage sensing and innate immunity converge to regulate tumour-host interactions	Claire Vanpouille
10.00 – 10.30		<i>Coffee break</i>	
10.30 – 11.15	45	Orchestration of immune attack against tumours	Fernanda Herrera
11.15 – 12.00	45	Clinical monitoring of radio-immunotherapy combinations	Udo Gaipl
12.00 – 13.00		<i>Lunch break</i>	
13.00 – 13.45	45	The GOOD, the ELDER & the BAD: vaccine & radiotherapy to fight cancer	Michele Mondini
13.45 – 14.30	45	The oligometastatic disease what is it and is it an opportunity for IO	Gosse Adema
14.30 – 15.00		<i>Coffee break</i>	
15.00 – 15.45	45	Microbiome immunotherapy and cancer	Jamie Honeychurch
15.45 – 16.30	45	Conventional markers, immunosuppression, what do we know?	Eric Deutsch

SCIENTIFIC PROGRAMME

DAY 3 – TUESDAY 5TH MARCH:**Topic VII: Clinical developments and future of immunoradiotherapy***Chair: TBC*

Time	Duration	Lecture	Speaker
08.30 – 09:15	45	Radiotherapy and immunotherapy combinations: lessons learnt from clinical trials	Eric Deutsch
09.15 – 10.00	45	Biomarkers of the immune response to radio (immuno) therapies	Gosse Adema
10.00 – 10.30		<i>Coffee break</i>	
10.30 - 11.15	45	The clinical landscape, progress and challenges in radioimmunotherapy for lung cancer	Rianne Vaes
11.15 - 12.00	45	Dose rate, an improvement of the immunological effects of radiotherapy	Fernanda Herrera
12.00– 12.30	30	Concluding remarks	Eric Deutsch / Udo Gaipl